PCSK9 Rekombinanter Antikörper
PCSK9 Rekombinant Antikörper für WB, IF/ICC, FC (Intra), ELISA
Wirt / Isotyp
Kaninchen / IgG
Getestete Reaktivität
human
Anwendung
WB, IF/ICC, FC (Intra), ELISA
Konjugation
Unkonjugiert
CloneNo.
241395G1
Kat-Nr. : 84172-4-RR
Synonyme
Geprüfte Anwendungen
| Erfolgreiche Detektion in WB | HepG2-Zellen |
| Erfolgreiche Detektion in IF/ICC | HepG2-Zellen |
| Erfolgreiche Detektion in FC (Intra) | HeLa-Zellen |
Empfohlene Verdünnung
| Anwendung | Verdünnung |
|---|---|
| Western Blot (WB) | WB : 1:500-1:2000 |
| Immunfluoreszenz (IF)/ICC | IF/ICC : 1:200-1:800 |
| Durchflusszytometrie (FC) (INTRA) | FC (INTRA) : 0.25 ug per 10^6 cells in a 100 µl suspension |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, check data in validation data gallery | |
Produktinformation
84172-4-RR bindet in WB, IF/ICC, FC (Intra), ELISA PCSK9 und zeigt Reaktivität mit human
| Getestete Reaktivität | human |
| Wirt / Isotyp | Kaninchen / IgG |
| Klonalität | Rekombinant |
| Typ | Antikörper |
| Immunogen | Rekombinantes Protein |
| Vollständiger Name | proprotein convertase subtilisin/kexin type 9 |
| Berechnetes Molekulargewicht | 74 kDa |
| Beobachtetes Molekulargewicht | 72-78 kDa, 62 kDa |
| GenBank-Zugangsnummer | NM_174936.4 |
| Gene symbol | PCSK9 |
| Gene ID (NCBI) | 255738 |
| Konjugation | Unkonjugiert |
| Form | Liquid |
| Reinigungsmethode | Protein-A-Reinigung |
| Lagerungspuffer | PBS with 0.02% sodium azide and 50% glycerol |
| Lagerungsbedingungen | Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA. |
Hintergrundinformationen
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a crucial protein governing the circulating levels of low density lipoprotein-cholesterol (LDL-C), by virtue of its pivotal role in the degradation of the LDL receptor (LDLR). PCSK9 is expressed in the kidney and lung. It is synthesized as a 72 kDa immature precursor that undergoes autocatalytic cleavage in the endoplasmic reticulum to generate a 63 kDa mature protein. The cleaved N-terminal fragment remains associated with the mature protein and is necessary for its secretion, allowing it to circulate in the blood. The ability of PCSK9 to regulate a diverse group of cell-surface proteins hinted that it might also be able to influence additional membrane proteins that are important in anti-tumour immune responses. Targeting PCSK9 to treat cancer is also attractive because two neutralizing antibodies against it, evolocumab and alirocumab, have already been approved for human clinical use to lower cholesterol levels. (PMID: 30522786, PMID: 22493497)
Protokolle
| PRODUKTSPEZIFISCHE PROTOKOLLE | |
|---|---|
| WB protocol for PCSK9 antibody 84172-4-RR | Protokoll herunterladen |
| IF protocol for PCSK9 antibody 84172-4-RR | Protokoll herunterladen |
| STANDARD-PROTOKOLLE | |
|---|---|
| Klicken Sie hier, um unsere Standardprotokolle anzuzeigen |




